ID: ALA4076543

Max Phase: Preclinical

Molecular Formula: C35H38N4O4

Molecular Weight: 578.71

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc(Nc2ccc(C(=O)N3CCOCC3)cc2)c(=O)n(C)c1

Standard InChI:  InChI=1S/C35H38N4O4/c1-23-29(7-6-8-30(23)37-32(40)24-9-13-27(14-10-24)35(2,3)4)26-21-31(34(42)38(5)22-26)36-28-15-11-25(12-16-28)33(41)39-17-19-43-20-18-39/h6-16,21-22,36H,17-20H2,1-5H3,(H,37,40)

Standard InChI Key:  FWFBJMDDPDNCHB-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 578.71

Molecular Weight (Monoisotopic): 578.2893

AlogP: 6.13

#Rotatable Bonds: 6

Polar Surface Area: 92.67

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: 2

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa:

CX Basic pKa:

CX LogP: 5.17

CX LogD: 5.17

Aromatic Rings: 4

Heavy Atoms: 43

QED Weighted: 0.29

Np Likeness Score: -1.38

References

1. Liang Q, Chen Y, Yu K, Chen C, Zhang S, Wang A, Wang W, Wu H, Liu X, Wang B, Wang L, Hu Z, Wang W, Ren T, Zhang S, Liu Q, Yun CH, Liu J..  (2017)  Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor.,  131  [PMID:28315597] [10.1016/j.ejmech.2017.03.001]

Source

Source(1):

• Scientific Literature